Drug
Anakinra
Anakinra: highest development phase Post-Market, developed by Amgen, Swedish Orphan Biovitrum. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Amgen, Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| Anakinra (Kineret®) NCT07706868 | Post-Market | Systemic Juvenile Idiopathic Arthritis (sJIA) |
| Anakinra NCT06666335 | Post-Market | Familial Mediterranean Fever (FMF ) |
| Anakinra (r-metHuIL-1ra) NCT00111410 | Post-Market | Rheumatoid Arthritis |
| anakinra NCT03265132 | Phase 3 | Still's Disease, Adult-Onset |
| Anakinra NCT05814159 | Phase 3 | Still's Disease, Juvenile Onset |
| anakinra NCT00037700 | Phase 2 | Rheumatoid Arthritis |
| Anakinra NCT00037648 | Phase 2 | Juvenile Chronic Arthritis |
| Anakinra 100 mg NCT03002974 | Phase 2 | Acute Gouty Arthritis |
Latest
No recent events.
Follow Anakinra on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.